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A b s t r a c t
Introduction: Obestatin is a 23-amino acid peptide derived from proghrelin, 
a  common prohormone for ghrelin and obestatin. Previous studies have 
shown that obestatin exhibits some protective and therapeutic effects in 
the pancreas and stomach. The aim of this study was to examine the effect 
of pretreatment with obestatin on the development of acetic acid-induced 
colitis.
Material and methods: Studies were performed on Wistar rats. Before in-
duction of colitis, rats were treated intraperitoneally with saline or obesta-
tin, administered twice at a dose of 4, 8 or 16 nmol/kg/dose. The first dose 
of saline or obestatin was administered 8 h before the induction of colitis, 
the second one 7 h after the first dose. Colitis was induced by enema with 
1 ml of 4% acetic acid solution. The severity of colitis was assessed 1 or 24 h 
after administration of enema.
Results: Pretreatment with obestatin administered at a dose of 8 or 16 nmol/
kg/dose significantly reduced the area of mucosal damage evoked by enema 
with acetic acid (p < 0.05). This effect was accompanied by an improvement 
of mucosal blood flow and DNA synthesis in the colon. Moreover, obestatin 
administered at a dose of 8 or 16 nmol/kg/dose significantly reduced muco-
sal concentration of IL-1β and activity of myeloperoxidase (p < 0.05).
Conclusions: Pretreatment with obestatin exhibited a  protective effect in 
the colon, leading to a  reduction of colonic damage in acetic acid-induced 
colitis. This effect was associated with an improvement of mucosal blood 
flow, an increase in mucosal cell proliferation, and a  decrease in local in-
flammation.
Key words: cell proliferation, blood flow, myeloperoxidase, interleukin-1β.
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Introduction
Inflammatory bowel disease (IBD), the main 
types of which are Cohn’s disease and ulcerative 
colitis, is a  group of chronic inflammations of 
the digestive tract [1]. They are characterized by 
a phasic course, with alternate periods of exacer-
bation and remission. According to epidemiologi-
cal studies the incidence of IBD is constantly rising 
[1–4]. Although the etiology of IBD is still unclear, 
available studies suggest that IBD results from an 
abnormal immunological response to microflora 
present in the digestive system, and their patho-
genesis is complex, requiring the co-existence of 
environmental and genetic factors [1, 4, 5]. There 
are numerous methods to ameliorate the signs 
and symptoms of IBD, but there is no method to 
permanent cure this disease [1, 5, 6]. This leads to 
a search for new therapeutic strategies.
Obestatin is a  23-amino acid peptide, dis-
covered in rat stomach and derived from pre-
proghrelin, which is a  common prohormone for 
ghrelin and obestatin [7, 8]. Secretion of obestatin 
is pulsatile and displays an ultradian rhythmicity 
similar to ghrelin and growth hormone [9]. Obes-
tatin exhibits opposite effects to ghrelin on gas-
trointestinal motility and energy metabolism. It 
has been reported to be an anorexic hormone, re-
ducing food intake, gastric emptying time, jejunal 
motility, and body weight gain [8–13].
Previous studies have shown that obestatin ex-
hibits protective and therapeutic effects in some 
organs of the gut [8]. It has been shown that 
treatment with obestatin accelerates the healing 
of acetic acid induced gastric ulcers [14]. The ther-
apeutic effect of obestatin has also been found 
in experimental colitis evoked by dextran sodium 
sulfate [15]. In the pancreas it has been demon-
strated that preventive administration of obes-
tatin inhibits the development of cerulein- and 
ischemia/reperfusion-induced acute pancreatitis 
[16, 17] and accelerates the healing of experi-
mental pancreatitis in rats [18, 19]. Also obestatin 
promotes survival of pancreatic islets, especially 
β-cells [20]. Moreover, clinical studies have shown 
that the obestatin/ghrelin ratio could serve as an 
index of IBD activity [21, 22].
The objective of the present study was to de-
termine the influence of pretreatment with obes-
tatin on the development of acetic acid-induced 
colitis in rats.
Material and methods
Animals and treatment
The research was performed on Wistar male 
rats weighing 250–270 g and conducted follow-
ing the experimental protocol approved by the 
First Local Commission of Ethics for the Care and 
Use of Laboratory Animals in Cracow (Permit No. 
2/2013). During the study, the animals were kept 
in cages placed at room temperature and a  12-
hour light-darkness cycle was maintained. The 
animals, prior to colitis induction with acetic acid 
solution, were fasted for 18 h with free access to 
water. Before and after this period food and tap 
water were available ad libitum.
One hundred twenty-eight rats were random-
ly divided into eight equal experimental groups: 
(1) control rats treated intraperitoneally (i.p.) with 
saline without induction of colitis; (2–4) rats treat-
ed i.p. with obestatin given at a dose of 4, 8 or 16 
nmol/kg/dose without induction of colitis; (5) rats 
treated i.p. with saline before induction of colitis; 
(6–8) rats treated i.p. with obestatin administered 
at a dose of 4, 8 or 16 nmol/kg/dose before induc-
tion of colitis.
The animals from each experimental group 
were divided into two equal sub-groups. In the first 
sub-groups, the severity of colitis was assessed 
1 h after the acetic acid enema. In the second sub-
groups, the severity of colitis was assessed 24 h 
after the acetic acid enema.
The experiments were repeated to obtain 8 an-
imals in each experimental group and each time 
of observation.
Saline or rat obestatin (Yanaihara Institute, Shi-
zuoka, Japan) was administered intraperitoneally 
according to the group of animals twice, 8 and 1 h 
before the rectal administration of saline or acetic 
acid solution. Obestatin was used at the doses of 
4, 8 and 16 nmol/kg/dose, because previous stud-
ies showed that these doses exhibited protective 
and therapeutic effects in the pancreas [16, 18] 
and stomach [14]. Obestatin was dissolved in sa-
line and then administered in an amount which 
did not exceed 0.3 ml/dose.
Before the induction of colitis, animals were 
anesthetized with ketamine (50 mg/kg i.p., Bio-
ketan, Vetoquinol Biowet, Gorzow Wielkopolski, 
Poland). Colitis was induced by intrarectal admin-
istration of 1 ml of 4% acetic acid aqueous solu-
tion through a  polyethylene catheter, which end 
was inserted into the bowel 4.5 cm deep from 
the anus. The animals without induction of colitis 
were treated with saline enema (sham operation).
Measurement of colonic blood flow  
and mucosal lesions
One or 24 h after enema, the rats were anes-
thetized again with ketamine. After opening the 
abdominal cavity and exposing the colon, the 
measurement of colonic blood flow volume was 
performed using a laser Doppler flowmeter (Peri-
Flux 4001 Master monitor, Perimed AB, Jarfalla, 
Sweden), in accordance with the methodology de-
scribed before [23]. The blood flow measurement 
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was performed each time in five different parts of 
the descending and sigmoid colon and the main 
value of five records was expressed as the per-
centage of the value obtained in the animals from 
the control group. After the measurement of the 
colonic blood flow, the area of mucosal damage 
was measured, using a computerized planimeter 
(Morphomat, Carl Zeiss, Berlin, Germany), in ac-
cordance with the method described earlier [24].
Biochemical analysis
After the measurement of the colonic blood 
flow and area of lesions, biopsy samples of the co-
lon were taken for determination of mucosal DNA 
synthesis (an index of mucosal cell proliferation), 
concentration of pro-inflammatory interleukin-1β, 
activity of myeloperoxidase, and for histological 
examination.
Determination of DNA synthesis in colonic 
mucosa
DNA synthesis was determined by measure-
ment of [3H]thymidine incorporation ([6-3H]-thy-
midine, 20–30 Ci/mmol, Institute for Research, Pro-
duction and Application of Radioisotopes, Prague, 
Czech Republic) into the mucosal DNA as described 
previously [25]. The incorporation of labeled thymi-
dine into DNA was determined by counting 0.5 ml 
of DNA-containing supernatant in a liquid scintil-
lation system. The rate of DNA synthesis was ex-
pressed as a number of tritium disintegrations per 
minute per μg of DNA (dpm/μg DNA).
Determination of interleukin-1β 
concentration in colonic mucosa 
The samples of the colonic mucosa were ho-
mogenized in ice-cold phosphate-buffered saline 
(PBS, 20 mM, pH 7.4). The homogenate was cen-
trifuged at 1,500 g for 10 min at 4°C. The content 
of interleukin-1β in the supernatant was mea-
sured using the Rat IL-1β Platinum Elisa (Bender 
MedSystem GmbH, Vienna, Austria). The concen-
tration of interleukin-1β in colonic mucosa was 
expressed as ng per g of tissue.
Determination of myeloperoxidase activity 
in colonic mucosa
The samples of colonic mucosa were frozen in 
liquid nitrogen, and, until the measurement was 
done, stored at –60°C. Myeloperoxidase activity 
was assessed using a modification of the method 
described by Bradley et al. [26]. The mucosa was 
homogenized in 1 ml of 50 mM potassium phos-
phate buffer (pH 6.0) containing 0.5% of hexadec-
yltrimethyl ammonium bromide. Then the homog-
enate was freeze-thawed three times, subjected to 
sonication in an ice bath for 20 s and centrifuged 
at 30,000 g for 15 min at 4°C. 100 μl of the su-
pernatant was taken and 2.9 ml of 50 mM phos-
phate buffer was added, which contained 157 μg/
ml of o-dianisidine dihydrochloride and 0.0005% 
hydrogen peroxide. Hydrogen peroxide reduction 
through myeloperoxidase causes oxidation of o-di-
anisidine and produces a stained final product. The 
intensity of staining was measured spectrophoto-
metrically with a light wavelength of 460 nm. The 
obtained results were calculated in units per gram 
of tissue and finally expressed as the percentage 
of the value observed in the control group.
Histological examination of the colon
Samples of the colon were fixed in 10% buff-
ered formaldehyde and embedded in paraffin. Par-
affin sections were stained with hematoxylin and 
eosin. Slides were examined by two experienced 
pathologists without knowledge of the treatment 
given. The histological grading of colonic damage 
was determined using a scale previously present-
ed by Vilaseca et al. [27]. The histological grad-
ing of lesions was made using a  scale ranging 
from 0 to 2 (0 = no lesions; 1 = small lesions 
< 3 mm; 2 = large lesions > 3 mm). Inflammato-
ry infiltration was graded from 0 to 3 (0 = none; 
1 small; 2 = moderate; 3 = heavy), depth of the 
lesions was graded from 0 to 3 (0 = no lesions; 
1 = lesions reaching submucosa; 2 = lesions 
reaching muscularis propria; 3 = lesions reaching 
serosa). The presence of fibrosis was grading from 
0 to 2 (0 = none; 1 = mild; 2 = severe).
Statistical analysis
The results were presented as the main value ± 
standard error (SEM). Statistical assessment was 
performed through one-way analysis of variance 
followed by Tukey’s multiple comparison test us-
ing GraphPad Prism (GraphPad Software, San Di-
ego, CA, USA). Statistical analysis was performed 
separately for each time of observation. Differenc-
es were considered to be statistically significant if 
p was less than 0.05.
Results
In the control saline-treated animals without 
induction of colitis, no lesions of the colon were 
observed in macroscopic or microscopic examina-
tion (Figures 1 and 2; Table I). Also administration 
of obestatin was without an effect on colonic mor-
phology in rats without induction of colitis (Figure 1; 
Table I). Rectal administration of 4% solution of 
acetic acid led to induction of colitis in all rats. 
In rats treated with saline, 1 h after the induc-
tion of colitis, the mucosal damage area was 4.9 
±0.4 mm², whereas after the next 23 h the area 
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Figure 1. Influence of pretreatment with obestatin 
given intraperitoneally at a dose of 4, 8 or 16 nmol/
kg/dose (O4, O8 or O16) on the area of colonic le-
sions observed 1 or 24 h after induction of colitis
Mean ± standard error. N = 8 animals in each group.  
ap < 0.05 compared to control at the same time of 
observation; bp < 0.05 compared to NaCl + colitis at the 
same time of observation.
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Figures 2. A – Representative microscopic image of colonic mucosa observed 1 h after enema with saline in sa-
line-pretreated control rats. B – Representative microscopic image of colonic mucosa observed 1 h after enema 
with acetic acid solution in saline-pretreated rats. C – Representative microscopic image of colonic mucosa ob-
served 1 h after enema with acetic acid solution in rats pretreated with obestatin given at a dose of 8 nmol/kg/
dose. D – Representative microscopic image of colonic mucosa observed 24 h after enema with saline in saline-pre-
treated control rats. E – Representative microscopic image of colonic mucosa observed 24 h after enema with acetic 
acid solution in saline-pretreated rats. F – Representative microscopic image of colonic mucosa observed 24 h after 
enema with acetic acid solution in rats pretreated with obestatin given at a dose of 8 nmol/kg/dose. Hematoxy-
lin-eosin stain. Original magnification 400×
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of colonic lesions enlarged to 32.3 ±2.5 mm² (Fig-
ure 1). In saline-treated animals with colitis, his-
tological examination performed 1 h after acetic 
acid enema showed the presence of large lesions 
reaching the level of the muscular membrane, 
with moderate inflammatory infiltration (Table I). 
Twenty-three hours later, histological examination 
showed an increase in the severity of colonic dam-
age. There were large lesion ulcers, reaching the 
muscular or serous membrane. These lesions were 
accompanied by severe inflammatory infiltration 
(Table I, Figure 2). In rats with colitis, pretreatment 
with obestatin reduced the development of colon-
ic damage. One hour after induction of colitis, the 
area of colonic damage was reduced by 19%, 45% 
or 35% in rats pretreated with obestatin given at 
a  dose of 4, 8 or 16 nmol/kg/dose, respectively. 
Twenty-three hours later, the area of the colonic le-
sion was reduced by 11%, 38% or 44% depending 
on the dose of obestatin (Figure 1). The reduction 
in the area of colonic damage evoked by obestatin 
given at a dose of 8 and 16 nmol/kg/dose was sta-
tistically significant in both times of observation, 
1 and 24 h after induction of colitis.
Pretreatment with obestatin also reduced his-
tological manifestation of colonic damage evoked 
by acetic acid (Table I, Figure 2). One hour after 
induction of colitis, the protective effect of pre-
treatment with obestatin was found as a decrease 
in grading and depth of lesions, as well as a  re-
duction in inflammatory infiltration of the colonic 
wall. Twenty-three hours later, the beneficial ef-
fect of pretreatment with obestatin was manifest-
ed, apart from the effects mentioned above, by in-
hibition of fibrosis development (Table I, Figure 2).
In the animals from the control group, DNA 
synthesis in colonic mucosa reached the value of 
38.2 ±1.9 and 37.5 ±2.8 dpm/μg DNA at the time 
of 1 and 24 h after the saline enema, respective-
ly (Figure 3). Pretreatment with obestatin, in the 
dosage used, did not exhibit a statistically signifi-
cant influence on the dynamics of DNA replication 
in colonic mucosa in animals without induction 
of colitis. One and 24 h after the rectal adminis-
Table I. Morphological signs of colonic damage observed 1 or 24 h after rectal administration of saline or acetic 
acid solution (colitis) in rats pretreated with saline or obestatin given at a dose of 4, 8 or 16 nmol/kg/dose (obes-
tatin 4, obestatin 8 or obestatin 16)
Variable Morphological changes
Grading of colonic 
damage
(0–2)
Inflammatory  
infiltration
(0–3)
Depth of damage
(0–3)
Fibrosis
(0–3)
1 h:
Saline (control) 0 0 0 0
Obestatin 4 0 0 0 0
Obestatin 8 0 0 0 0
Obestatin 16 0 0 0 0
Saline + colitis 2 2 2 1
Obestatin 4 + colitis 1–2 2 2 1
Obestatin 8 + colitis 1 1–2 1 1
Obestatin 16 + colitis 1 1–2 1 1
24 h:
Saline (control) 0 0 0 0
Obestatin 4 0 0 0 0
Obestatin 8 0 0 0 0
Obestatin 16 0 0 0 0
Saline + colitis 2 3 2–3 2
Obestatin 4 + colitis 1–2 2–3 2 1
Obestatin 8 + colitis 1–2 2 1 1
Obestatin 16 + colitis 1–2 2 1 1
Numbers represent the predominant histological grading in each group.
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tration of acetic acid solution, DNA synthesis was 
significantly reduced by around 50% and 62%, re-
spectively. Prior administration of obestatin par-
tially reversed that effect. Pretreatment with obes-
tatin given at a dose of 8 or 16 nmol/kg/dose led 
to a statistically significant, similar in the case of 
both doses, improvement of DNA replication in the 
colon mucous membrane, in the animals with coli-
tis. This effect was observed at both times of ob-
servation, 1 and 24 h after the induction of colitis 
(Figure 3). In contrast, pretreatment with obesta-
tin given at a dose of 4 nmol/kg/dose was without 
an effect on mucosal DNA synthesis in the colon 
of rats with acetic acid-induced colitis (Figure 3).
In the groups of animals without the induction 
of colitis, double intraperitoneal administration of 
obestatin in the doses used failed to affect the mu-
cosal blood flow in the colon (Figure 4). Induction 
of colitis led to a statistically significant decrease 
in the blood flow through the colonic mucosa by 
almost 72% and 77%, respectively after 1 and 24 h 
after the enema with acetic acid solution (Figure 4). 
Prior double administration of obestatin, given at 
a dose of 8 or 16 nmol/kg/dose, significantly re-
versed the colitis-evoked decrease in the mucosal 
blood flow in the colon. This effect of obestatin 
was found at both times of observation, 1 and 
24 h after the induction of colitis. The effect of 
obestatin administered at a  dose of 4 nmol/kg/
dose on mucosal blood flow was weak and statis-
tically insignificant (Figure 4).
In the control rats, mucosal concentration of 
pro-inflammatory IL-1β in the colon was around 
0.80 ng/g of tissue (Figure 5). Treatment with any 
dose of obestatin was without a significant effect 
on the mucosal IL-1β level in the rats without coli-
tis. Administration of 4% solution of acetic acid 
increased the mucosal IL-1β concentration by 
50% and 600% at 1 and 24 h after induction of 
colitis, respectively. Pretreatment with obestatin 
at a dose of 8 and 16 nmol/kg/dose reduced the 
colitis-evoked increase in mucosal IL-1β concen-
tration. This effect was statistically significant at 
1 and 24 h after induction of colitis in rats pre-
treated with obestatin given at a dose of 16 nmol/
kg/dose. In the case of animals pretreated with 
obestatin given at a  dose of 8 nmol/kg/dose, 
a significant reduction in mucosal IL-1β concentra-
tion was observed 24 h after induction of colitis. 
One hour after induction of colitis, pretreatment 
with obestatin given at a dose of 8 nmol/kg/dose 
reduced mucosal IL-1β concentration, but this ef-
fect was statistically insignificant in comparison 
to the value observed in saline-treated animals 
with colitis (Figure 5). Pretreatment with obestatin 
administered at a dose of 4 nmol/kg/dose failed 
to affect the mucosal concentration of IL-1β in the 
colon of animals with colitis (Figure 5).
Administration of obestatin given at the dos-
es used failed to have a significant effect on the 
mucosal myeloperoxidase (MPO) activity in the co-
lon of rats without induction of colitis (Figure 6). 
One hour after the enema with acetic acid, MPO 
activity in colonic mucosa was increased almost 
by 100%, whereas 23 h later almost a 5-fold in-
crease in MPO activity in colonic mucosa was ob-
served. Pretreatment with obestatin reduced the 
colitis-evoked increase in colonic activity of MPO. 
The effect of obestatin, administered at a dose of 
4 nmol/kg/dose, was statistically insignificant at 
both times of observation. In contrast, obestatin 
given at a dose of 8 or 16 nmol/kg/dose signifi-
Figure 3. Influence of pretreatment with obestatin 
given intraperitoneally at a dose of 4, 8 or 16 nmol/
kg/dose (O4, O8 or O16) on DNA synthesis in co-
lonic mucosa observed 1 or 24 h after induction of 
colitis
Mean ± standard error. N = 8 animals in each group.  
ap < 0.05 compared to control at the same time of 
observation; bp < 0.05 compared to NaCl + colitis at the 
same time of observation.
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Figure 4. Influence of pretreatment with obesta-
tin given intraperitoneally at a dose of 4, 8 or 16 
nmol/kg/dose (O4, O8 or O16) on mucosal blood 
flow in the colon observed 1 or 24 h after induction 
of colitis
Mean ± standard error. N = 8 animals in each group.  
ap < 0.05 compared to control at the same time of 
observation; bp < 0.05 compared to NaCl + colitis at the 
same time of observation.
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cantly inhibited the mucosal MPO activity in the 
colon of the animals with colitis. This inhibitory 
effect was similar for both above doses of obesta-
tin and was observed at both 1 and 24 h after the 
induction of colitis (Figure 6).
Discussion
This study provided important observations 
showing that obestatin affects maintenance of 
the integrity of the mucous membrane in the 
colon. Pretreatment with obestatin inhibited the 
development of acetic acid-induced colitis in rats, 
which was found as a decrease in the area of co-
lonic damage. This effect was associated with the 
improvement of mucosal blood flow and DNA syn-
thesis, and with a reduction in the colitis-evoked 
increase in mucosal IL-1β concentration and my-
eloperoxidase (MPO) activity.
Preservation of the integrity of gastrointestinal 
mucosa is dependent on maintaining a dynamic 
balance between damaging factors acting on the 
mucous membrane and mechanisms responsible 
for mucosa protection. Adequate cell proliferation 
plays an important role among the mechanisms 
responsible for integrity of gastrointestinal muco-
sa. Reduction in cell proliferation, excessive apop-
tosis and increased cell loss play a key role in the 
development of mucous membrane atrophy and 
ulcers [28, 29]. On the other hand, increased cell 
renewal leads to increased mucosal protection in 
the gastrointestinal tract and promotes healing of 
the damage in the gut [30–33]. Mucosal cells are 
reconstructed by mitosis of stem and progenitor 
cells. DNA synthesis occurs in the S phase during 
the cell cycle and it is mandatory for cell division 
[33]. It can be concluded that DNA synthesis dy-
namics reflect the vitality of cells, as well as cell 
proliferation. As a result of our present research, 
it was demonstrated that rectal administration of 
acetic acid led to a considerable decrease in DNA 
synthesis in the colonic mucous membrane. That 
decrease was well correlated with the expanse of 
the area of inflammation. It indicates that there 
is a  relationship between cell proliferation and 
pathogenesis of acetic-acid-induced colitis. Our 
present study has also shown that administration 
of obestatin in the animals without colitis induc-
tion had no significant influence on DNA synthe-
sis in colonic mucosa. This finding indicates that 
administration of obestatin at these doses does 
not induce cell hyperproliferation and mucosal hy-
pertrophy in animals with normal mucosa. In con-
trast to that, pretreatment with obestatin before 
induction of colitis led to partial, but significant 
reversion of the colitis-evoked decrease in muco-
sal DNA synthesis. This observation indicates that 
improvement of cell vitality and proliferation is in-
volved in the protective effect of obestatin in the 
colon.
Vascular mechanisms play a key role in the pro-
cesses of protection and healing of mucosa in the 
gut [34–36]. Experimental studies have demon-
strated that a  decrease in gastric blood flow in-
creases the severity and area of gastric ulcers after 
exposure of gastric mucosa to damaging factors 
[34]. Similar effects of reduction in organ blood 
flow on mucosal integrity have been observed in 
other parts of the digestive tract such as the oral 
cavity [35], esophagus [36], duodenum [37] and 
colon [38]. Our present results are in agreement 
with those observations. Rectal administration 
Figure 5. Influence of pretreatment with obestatin 
given intraperitoneally at a dose of 4, 8 or 16 nmol/
kg/dose (O4, O8 or O16) on interleukin-1β concen-
tration in colonic mucosa observed 1 or 24 h after 
induction of colitis
Mean ± standard error. N = 8 animals in each group.  
ap < 0.05 compared to control at the same time of 
observation; bp < 0.05 compared to NaCl + colitis at the 
same time of observation.
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Figure 6. Influence of pretreatment with obestatin 
given intraperitoneally at a dose of 4, 8 or 16 nmol/
kg/dose (O4, O8 or O16) on myeloperoxidase ac-
tivity in colonic mucosa observed 1 or 24 h after 
induction of colitis
Mean ± standard error. N = 8 animals in each group.  
ap < 0.05 compared to control at the same time of 
observation; bp < 0.05 compared to NaCl + colitis at the 
same time of observation.
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of acetic acid solution led to a reduction in blood 
flow in the colon, and this effect was associated 
with the development of colonic wall damage. 
Our present study also showed that administra-
tion of obestatin prior to colitis induction caused 
the improvement of blood flow in colonic muco-
sa, leading to a  decrease in the area and sever-
ity of colonic mucosa damage. That observation 
suggests that the protective effect of obestatin on 
the colonic mucosa is related, at least in part, to 
improvement of blood flow in this membrane.
In this study, we evaluated the severity of coli-
tis by measurement of mucosal concentration of 
IL-1β and MPO activity. IL-1β plays an essential 
role in the development of local and systemic in-
flammation [39]. This pro-inflammatory cytokine 
is mainly produced by monocytes and tissue mac-
rophages. Interleukin-1β is involved in mediating 
both acute and chronic inflammation. It initiates 
the inflammatory cascade by activating the ex-
pression of further pro-inflammatory cytokines, 
mainly interleukin-6, TNF-α and prostaglandins 
[39, 40]. Interleukin-1β is synthesized in imma-
ture form, which is proteolytically processed to its 
active form by caspase-1 [41]. The interleukin-1 
gene cluster has been mapped to the long arm 
of chromosome 2 and consists of three genes, 
IL-1α, IL-1β and IL-1 receptor antagonist genes, 
encoding IL-1α, IL-1β and IL-1 receptor antago-
nist proteins, respectively [42]. There are studies 
suggesting that some kinds of polymorphisms in 
the IL1B gene are associated with an increased 
risk of diseases such as chronic obstructive pul-
monary disease [43] or chronic periodontitis [44]. 
In the experimental and clinical research, it has 
been demonstrated that administration of a  re-
ceptor antagonist or immunoglobulins against 
IL-1β prevents the increase in IL-6 and TNF-α in 
inflammation, as well as decreasing the severity 
of inflammation [40, 45–48]. Our present study 
indicated that acetic-acid-induced colitis leads to 
an increase in mucosal concentration of IL-1β in 
the colon. Prior administration of obestatin part-
ly, although significantly, reversed that effect. In 
contrast, administration of obestatin in animals 
without colitis did not affect IL-1β concentration 
in colonic mucosa.
The grade of tissue infiltration by neutrophil 
granulocytes is reflected by the level of MPO activ-
ity because it is an enzyme that is present in gran-
ularities of these cells [49, 50]. During inflamma-
tion, MPO is released from neutrophils, leading to 
the creation of hypochlorous acid and other free 
radicals, which have strong bactericidal and anti-
viral properties. However, free radicals which are 
created in this process also cause damage to host 
cells by destroying proteins, DNA and lipids [50]. 
In the present research, enema with acetic acid 
solution led to a  significant and potent increase 
in myeloperoxidase activity in the colonic muco-
sa. Prior administration of obestatin, in animals 
in which colitis was induced, led to a significant 
reduction in the colitis-evoked increase in MPO 
activity in the colonic mucosa. On the other hand, 
administration of obestatin failed to affect MPO 
activity in the colonic mucosa in animals in which 
colitis was not induced.
The effects of obestatin on IL-1β concentra-
tion and MPO activity in colonic mucosa in rats 
with colitis suggest that the protective effect of 
obestatin is related to the inhibitory impact on 
the development of inflammation. The lack of 
effects of pretreatment with obestatin on mu-
cosal IL-1β and MPO in animals without colitis 
suggests that this polypeptide has no influence 
on the immune system activity, as well as mi-
gration, and activity of leukocytes in the colon 
without inflammation.
In conclusion, our present results indicate that 
pretreatment with obestatin protects the colonic 
mucosa against acetic acid-induced damage. This 
observation suggests the potential applicability of 
this peptide in maintenance of IBD patients in re-
mission.
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